<DOC>
	<DOCNO>NCT02106494</DOCNO>
	<brief_summary>The primary study objective demonstrate superiority APF530 500 mg give subcutaneously ( SC ) compare ondansetron 0.15 mg/kg give intravenously ( IV ) ( maximum 16 mg ) delayed-phase ( &gt; 24-120 hour ) complete response ( CR ) rate ( define emesis use rescue medication ) subject receive highly emetogenic chemotherapy ( HEC ) define 2011 ASCO CINV guideline</brief_summary>
	<brief_title>A Prospective , Multicenter , Study APF530 ( Granisetron ) SC Prevention CINV Patients Receiving HEC</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subjects male nonpregnant female 1887 year age time enrollment . Subjects must histologically cytologically confirm malignant disease . Subjects must undergo treatment HEC regimen accord 2011 ASCO CINV guideline detail emetogenic classification chemotherapy agent study ) . A life expectancy &gt; 6 month Subjects must able receive standardized dos dexamethasone require protocol prevention emesis . Subjects must characterize Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Subjects must adequate bone marrow , kidney , liver function . Subjects must able swallow oral medication ( pill ) without difficulty . Subjects must enter first cycle current chemotherapy regimen . Subjects must willing able comply test requirement define protocol . Subjects must able provide voluntary , write , inform consent participate study must able fully understand study requirement . Female subject pregnant must adequately protected conception duration study , use least one form contraception . It recommend female female partner male subject remain adequately protect conception study 1 year follow study participation . Subject know hypersensitivity granisetron 5HT3 receptor antagonist . Subject history presence clinically significant abnormal 12lead ECG ECG QTc Bazett 's correction &gt; 450 msec men &gt; 470 msec woman screen ECG . Subject PR &gt; 240 msec , QRS &gt; 110 msec , history prolongation QT interval . Subject family history long QT syndrome . Subject history cardiac disease , include congenital long QT syndrome , angina , myocardial ischemia infarction , congestive heart failure , myocarditis , chest pain dyspnea exertion . Subject electrolyte disturbance , uncorrected hypokalemia/hyperkalemia , hypomagnesemia , hypocalcemia . Subject idiopathic cardiomyopathy , syncope , epilepsy , hypertrophic cardiomyopathy , clinically significant cardiac disease . Subject pregnant breastfeeding . Subject plan receive multipleday chemotherapy . Subject take follow agent within 7 day prior initiation chemotherapy ( study ) : 5HT3 receptor antagonist , phenothiazine , benzamides , domperidone , cannabinoids , NK1 receptor antagonist . Subject take benzodiazepine within 1 day ( 24 hour ) prior initiation chemotherapy ( study ) . Subject schedule receive chemotherapeutic agent Day 2 Day 6 . Subject schedule receive radiation therapy abdomen pelvis Day 5 Day 6 . Subject receive systemic corticosteroid sedative antihistamine within 72 hour Day 1 study , except premedication chemotherapy ( e.g. , taxanes , pemetrexed ) . Subject symptomatic primary metastatic central nervous system ( CNS ) disease . Subject ongoing vomiting , retch , nausea cause etiology , history anticipatory nausea vomit . Subject vomited and/or dry heave retch within 24 hour prior start HEC Day 1 . Subject NOT able swallow oral medication ( pill ) without difficulty .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>87 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Highly emetogenic chemotherapy ( HEC )</keyword>
	<keyword>Chemotherapy-Induced Nausea Vomiting ( CINV )</keyword>
</DOC>